ReNeuron Group PLC (LON:RENE) has won the Breakthrough of the Year award at the 2019 Mediscience Awards in London for the clinical development and commercial progress it has made over the past year.
The developer of stem cell technologies said the award acknowledges positive data from its ongoing phase I/II clinical trial of its hRPC treatment for a rare blindness-causing disease called retinitis pigmentosa.
READ: ReNeuron well funded for pivotal period clinically and commercially
Another recent highlight for the group was the signing of an exclusive licence agreement with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. for the development, manufacture and commercialisation of ReNeuron's cell therapy programmes in China.
"We are delighted to have been awarded the Breakthrough of the Year award at the 2019 European Mediscience Awards,” said ReNeuron chief executive Olav Hellebø.
“We are greatly encouraged by the progress we have made with our cell therapy clinical development programmes for retinitis pigmentosa and stroke disability over the past year and look forward to continuing to advance our clinical and business development activities in the months ahead."